Posted by Michael Wonder on 15 Sep 2018
Patient groups attack CVS use of ICER metrics, urge rethink
14 September 2018 - More than 90 organisations, predominantly patient groups, criticised CVS Caremark's decision last month to incorporate value-based drug pricing analyses in some of its coverage choices, urging the company to reconsider in a letter addressed to CVS CEO Larry Merlo.
The rhetorical war between PBMs and drugmakers on how to value and pay for medicines has drawn in patient groups, which are concerned that attempts to minimize costs could limit access to new treatments.
In last month's announcement, CVS said it would exclude certain drugs that carry list prices which come in above a threshold of $100,000 per QALY — a measure that attempts to define a drug's value.
